Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. insider Sheena Jonathan, a director and co‑founder, reported pre‑planned sales of common stock held by family trusts. Caraluna 1 and Caraluna 2 Trusts sold a total of 1,500 shares on July 15, 2026 at weighted‑average prices between $272.56 and $276.38 per share under a Rule 10b5-1 trading plan adopted June 7, 2024. The shares are held for trust beneficiaries, and Jonathan disclaims beneficial ownership. A separate holdings entry reports 246,202 common shares held directly.
Natera, Inc. director Rowan E Chapman sold 135 shares of Common Stock on July 15, 2026 at an average price of $274.82 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on December 12, 2025, leaving Chapman with 4,663 shares held directly.
Natera, Inc. director and co‑founder Sheena Jonathan reported open‑market sales of 3,150 shares of common stock on July 13, 2026, at weighted‑average prices from $262.7160 to $268.3870 per share under a Rule 10b5‑1 trading plan adopted December 12, 2025. After these transactions, she reports 246,202 shares held directly, and 18,782 shares in each of the Caraluna 1 Trust and Caraluna 2 Trust held for trust beneficiaries, for which she disclaims beneficial ownership.
Rowan Emma Chapman, a security holder of issuer NTRA, filed a Form 144 indicating a planned sale of 135 common shares through Morgan Stanley Smith Barney on NASDAQ around July 15, 2026, with an indicated value of 37,100.70. A prior transaction on June 16, 2026 involved 2,964 common shares with total proceeds of 642,535.92. The notice also references restricted stock acquisitions of 68 and 67 common shares in late June 2025.
Jonathan Sheena submitted a notice of proposed sale for 1,500 shares of common stock to be sold through Charles Schwab & Co. on July 15, 2026, with an aggregate market value of $412,830.00 on NASDAQ. These are founders shares acquired from the issuer on April 30, 2012. Over the past three months, he reported several sales of common stock, including 3,071 shares for $603,198.00 on April 29, 2026 and 3,150 shares for $836,898.00 on July 13, 2026.
Natera, Inc. investor Jonathan Sheena filed a notice to sell up to 9,450 shares of common stock through Charles Schwab & Co., Inc. The shares have an aggregate market value of $2,515,779.00, with Natera common stock listed on NASDAQ. The notice references Natera’s 143,215,382 shares outstanding and includes a history of multiple common stock sales during the past three months.
Natera, Inc. executive chairman Matthew Rabinowitz reported insider transactions involving the company’s common stock. On July 6, 2026, his spouse completed an open‑market sale of 1,000 shares at $280 per share under a pre‑arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following this sale, indirect holdings by his spouse totaled 4,000 shares, while Rabinowitz’s direct ownership stood at 2,277,843 shares, indicating the sale was small relative to his overall position.
Natera, Inc. insider Daniel Rabinowitz, the Secretary and Chief Legal Officer, sold 16,800 shares of Common Stock in a series of open‑market transactions. The sales occurred on July 1, 2026 and were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 5, 2025.
The reported sales were broken into multiple trades at weighted‑average prices, with underlying individual trade prices ranging from about $266.33 to $278.78 per share, according to the footnotes. The filing does not change any company fundamentals; it simply discloses these planned insider stock sales.
Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported selling 3,000 shares of Natera common stock in open-market transactions on July 1, 2026. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024, indicating the trades were scheduled in advance. Reported weighted average prices were about $274.06, $272.99, and $267.19 per share, with actual trade prices ranging between $267.05 and $273.00. Moshkevich continues to hold a direct equity stake in Natera after these sales.
Matthew Rabinowitz reported multiple sales of Common stock as disclosed on Form 144. The filing lists two 50,000-share sales on 06/15/2026 and 06/12/2026, and several smaller dispositions between 04/28/2026 and 05/06/2026. Each transaction shows the share count and gross proceeds.